Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 5Unknown 2Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 16Breast 13Genitourinary 8Thoracic 7Head & Neck 4CNS 4Sarcoma 3Gynecologic 2Endocrine 2Dermatologic 2Tumor-Agnostic 1NET 1

Conditions

Neuroendocrine Tumors 1Insulinoma 1

Interventions

lutetium Lu 177 dotatate 14Nivolumab 12Magnetic Resonance Spectroscopy 11pembrolizumab 10Specimen Handling 10Ipilimumab 9cabozantinib 8trametinib 6lenvatinib 6Temozolomide 6dabrafenib 4atezolizumab 4Lutetium-177 4Immunoglobulin G 4Everolimus 4Disulfides 4CTLA-4 Antigen 4selpercatinib 3Octreotide 3Cisplatin 3Carboplatin 3Capecitabine 3Bevacizumab 3entrectinib 2copper dotatate CU-64 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Vemurafenib 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Surgical Procedures, Operative × Endocrine × Clear all
NCT05735912 2026-01-13

ERASIN-RCT

Azienda Ospedaliera Universitaria Integrata Verona

Phase NA Active not recruiting
60 enrolled
Endocrine

Insulinoma

NCT03012789 2024-04-30

NETest_Sx

Wren Laboratories LLC

Phase NA Active not recruiting
40 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡